| US 7,470,660 B2 | ||
| Treatment for dark adaptation | ||
| Daniel M. Schwartz, San Francisco, Calif. (US); Keith G. Duncan, San Francisco, Calif. (US); Kathy Bailey, San Francisco, Calif. (US); John P. Kane, Hillsborough, Calif. (US); and Brian Y. Ishida, Walnut Creek, Calif. (US) | ||
| Assigned to The Regents of the University of California, Oakland, Calif. (US) | ||
| Filed on Feb. 10, 2005, as Appl. No. 11/55,309. | ||
| Application 11/055309 is a division of application No. 10/794198, filed on Mar. 05, 2004. | ||
| Application 10/794198 is a continuation in part of application No. 10/428551, filed on May 02, 2003. | ||
| Application 10/428551 is a continuation in part of application No. 10/313641, filed on Dec. 06, 2002, abandoned. | ||
| Claims priority of provisional application 60/340498, filed on Dec. 07, 2001. | ||
| Claims priority of provisional application 60/415864, filed on Oct. 03, 2002. | ||
| Prior Publication US 2005/0282750 A1, Dec. 22, 2005 | ||
| Int. Cl. A61K 31/685 (2006.01); A61K 31/7088 (2006.01); A61K 38/02 (2006.01); A61K 38/10 (2006.01); A61K 38/17 (2006.01) | ||
| U.S. Cl. 514—2 [514/12; 514/13; 514/21; 514/44; 514/78] | 12 Claims |
| 1. A method of improving impaired dark adaptation in an individual, comprising the steps of:
identifying an individual afflicted with impaired dark adaptation; and
delivering to the individual a therapeutically effective amount of a composition comprising ApoA-I.
|